The firm said today that it has received all regulatory clearances to close the deal that it first proposed in February 2016.
The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order.
Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.
Abbott said that greater than 90 percent of the issued and outstanding shares of preferred stock had been tendered as of Sept. 15.
The firm extended its cash tender offer for all outstanding shares of Alere's Series B convertible perpetual preferred stock until the end of the day on Sept. 15.
The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.
Alere's financial results in the prior-year period reflected restatements of revenues stemming from incorrectly recorded revenue transactions.
The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.
Abbott CEO Miles White said that he is confident that Abbott's acquisition of Alere will close as expected before the end of Q3.
Canaccord and William Blair also increased their price targets on Quidel's shares, following its acquisition of certain Alere assets and assays.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.